KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares Repurchased
Ratios

Sarepta Therapeutics (SRPT) Receivables Refunds (2023 - 2025)

Sarepta Therapeutics (SRPT) has 3 years of Receivables Refunds data on record, last reported at $7.0 million in Q1 2025.

  • For Q1 2025, Receivables Refunds changed N/A year-over-year to $7.0 million; the TTM value through Mar 2025 reached $7.0 million, changed N/A, while the annual FY2024 figure was $13.1 million, 91.37% up from the prior year.
  • Receivables Refunds reached $7.0 million in Q1 2025 per SRPT's latest filing, down from $13.1 million in the prior quarter.
  • Across five years, Receivables Refunds topped out at $13.1 million in Q4 2024 and bottomed at $6.9 million in Q4 2023.
  • Average Receivables Refunds over 3 years is $8.9 million, with a median of $7.7 million recorded in 2024.
  • The widest YoY moves for Receivables Refunds: up 91.37% in 2024, down 91.37% in 2024.
  • A 3-year view of Receivables Refunds shows it stood at $6.9 million in 2023, then skyrocketed by 91.37% to $13.1 million in 2024, then plummeted by 46.5% to $7.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables Refunds were $7.0 million in Q1 2025, $13.1 million in Q4 2024, and $8.4 million in Q2 2024.